个人简介

曹治兴，博士、副研究员、硕士生导师、就职于药学院；四川省国际医学交流促进会青年委员。研究方向为中药药理学，主要从事中药抗肿瘤、抗炎和抗病毒相关有效成分活性筛选、靶标探索、作用机制及相关新药研发研究，并探索新型模式动物斑马鱼在中药活性评价中的应用；已获得国家自然科学基金项目1项，中国博士后基金面上项目1项，参与四川省科技厅创新团队项目、重大科技支撑计划项目和四川省中医药管理局项目多项。至今，以第一作者或通讯作者身份已在Leukemia、Clin Cancer Res、J.Med.Chem、Pharmac Res、FASEB J、Mol Pharm、J Nat Prod、J Ethnopharm、Oncotarget、Nat Prod Res、J Zool等国际知名SCI期刊发表论文十余篇；申请发明专利5项，授权2项。

代表性成果 

1.Zhixing Cao#, Chuanjie Guo#, Xiaominting Song, Junlin He, Lu Tan, Si Yu, Ruoqi Zhang, Fu Peng, Cheng Peng* and Yuzhi Li*. Erlotinib is effective against FLT3-ITD mutant AML and has the potential to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB J, 2020, accepted

2.Yumei Cao, Dale Guo, Mengying Jin, Lu Tan, Tianlong Yang, Fang Deng, Yu cheng Gu, Xiaohua Li, Zhixing Cao⁎, Yun Deng⁎. Two new nor-sesquiterpenoids from Fusarium tricinctum, an endophytic fungus isolated from Ligusticum chuanxiong. Nat Prod Res. 2020 Jan 24:1-5. 

3.Chuanjie Guo, Junlin He, Xiaominting Song, Lu Tan, Miao Wang, Peidu Jiang, Yuzhi Li, Zhixing Cao⁎, Cheng Peng⁎. Pharmacological properties and derivatives of shikonin-A review in recent years. Pharmacol Res. 2019 Nov;149:104463

4.Zhixing Cao#, Yi Wen#, Jun-Lin He, Shen-Zhen Huang, Fei Gao, Chuan-Jie Guo, Qing-Qing Liu, Shu-Wen Zheng, Dao-Yin Gong, Yu-Zhi Li, Ruo-Qi Zhang, Jian-Ping Chen, Cheng Peng. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo. Mol Pharmacol. 2019 Nov;96(5):589-599

5.Yuzhu Tan, Cheng Peng*, Chang-Jiang Hu, Hong-Xiang Li, Wen-Bing Li, Jun-Lin He, Yu-Zhi Li, Hai Zhang, Ruo-Qi Zhang, Li-Xia Wang, Zhixing Cao*. Iridoids from Valeriana jatamansi induce autophagy-associated cell death via the PDK1/Akt/mTOR pathway in HCT116 human colorectal carcinoma cells. Bioorg Chem. 2019 Jun;87:136-141. 

6.Ye Ye, Drolma Dawa, Guang-Hui Liu, Min Zhao, Dorje Tseden, Yucheng Gu, Lisheng Ding, Zhixing Cao*, and Yan Zhou*. Antiproliferative Sesquiterpenoids from Ligularia rumicifolia with Diverse Skeletons. Journal of natural products, 2018, 81(9): 1992-2003.

7.Yuzhi Li#, Si Yu#, Peiao Yan, Daoyin Gong, Fangli Wu, Zhi He, Yuyao Yuan, Anyan Zhao, Xue Tang, Ruoqi Zhang, Cheng Peng* and Zhixing Cao*, Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. Oncotarget, 2017, 8(61): 103087–103099

8.Lei Zhong#, Jiao Yang#, Zhixing Cao#, Xin Chen, Yiguo Hu, Linli Li*, Shengyong Yang*, Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer, Oncotarget, 2017: 8(8),12843-12854

9.Zhixing Cao#, Yuting Yang#, Si Yu, Yuzhi Li, Wenwen Wang, Jing Hua9.g, Xiaofang Xie, Liang Xiong, Song Lei, Cheng Peng*, Pogostone Induces Autophagy and Apoptosis Involving PI3K/Akt/mTOR Axis in Human Colorectal Carcinoma HCT116 cells, Journal of Ethnopharmacology, 2016: 202, 20-27

10.Zhixing Cao, Jingjing Liu, Renlin Zheng, Jiao Yang, Lei Zhong, Yong Xu, Lijiao Wang, Chunhui Zhang, Binglin Wang, Shuang Ma, Zerong Wang, Huanzhang Xie, Yuquan Wei, Shengyong Yang*, SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in that of CML harboring Abl mutants. Leukemia, 2012: 26, 1892-1895

11.Weiwei Li#, Xiaowan Wang#, Renlin Zheng#, Hengxiu Yan#, Zhixing Cao#, Lei Zhong, Zerong Wang, Pan Ji, Lingling Yang, Lijiao Wang, Yong Xu, Jingjing Liu, Jiao Yang, Chunhui Zhang, Shuang Ma, Shan Feng, Qizheng Sun,Yuquan Wei, Shengyong Yang*, Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-(5-(7-(3-Morpholinopropoxy)quinazolin-4-ylthio)-1,3,4-thiadiazol-2-yl)-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in vitro and in vivo, J. Med. Chem, 2012, 55 (8): 3852–3866

12.Zhixing Cao#, Renlin Zheng#, Hongjun Lin#, Shidong Luo, Yan Zhou,  Youzhi Xu, Xiuxiu Zeng, Zhao Wang, Lina Zhou, Yongqiu Mao, Li Yang,  Yuquan Wei, Luoting Yu, Shengyong Yang, Yinglan Zhao*, SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo, Cell Physiol Biochem, 2011, 27: 565-574

13.Shuang Zhang#, Zhixing Cao#, Hongwei Tian, Guobo Shen, Yongping Ma, Huanzhang Xie, Yalin Liu, Chengjian Zhao, Senyi Deng, Yang Yang, Renlin Zheng, Weiwei Li, Na Zhang, Shengyong Liu, Wei Wang, Lixia Dai, Shuai Shi, Lin Cheng, Youli Pan, Shan Feng, Xia Zhao, Hongxin Deng*, Shengyong Yang*, Yuquan Wei, SKLB1002, A Novel Potent Inhibitor of Vascular Endothelial Growth Factor Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth in Vivo, Clin Cancer Res July 1, 2011, 17: 4439-50